Cases & Deals

Amolyt Pharma raises $138 million in Series C financing

Client(s) Amolyt Pharma

Jones Day advised Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, in connection with its $138 million Series C financing led by Sofinnova Partners and co-led by Intermediate Capital Group (ICG), along with Tekla Capital Investment LLC, and CTI Life Sciences as well as existing investors, including, Andera Partners, Kurma, Bpifrance (Innobio), Sectoral, and Pontifax.